Sentences with phrase «more clinical in»

There's no adventure here, everything feels more clinical in No Man's Sky, unmemorable.

The Reds dominated the possession stats against Spurs on Sunday afternoon, but the north London club were just more clinical in front of goal with Harry Kane bagging yet another brace.

They will hope to be a lot more clinical in the final third of the pitch from here on out though.

Arsenal were far more clinical in the attacking third on Sunday, with their neat interchanging too much for Bolton to handle.

If we can bring in consistency and be more ruthless, be more clinical in situations because of confidence and all that stuff, then we can win games.

Despite this, the 25 - year - old has the tendency to miss clear - cut chances, and he may have to be more clinical in front of goal versus the Premier League leaders.

As mentioned I am perfectly happy with Firmino being our first choice striker, apart from becoming a bit more clinical in front of goal, he is close to being a very complete striker and fits Klopp's system perfectly.

Jesse seems to understand José's tactics better than Martial and Rashford, if he was more clinical in taking his chances I do nt think his selection would be up for debate.

«We pressed quite well in the first half but needed to be more clinical in the final third.

His shot accuracy rate was 42 %, which isn't bad but it is just about being more clinical in front of goal when the chance comes.

Benzema was more clinical in the Champions League (Giroud only featured twice), but Giroud had more attempts at a higher conversion rate, with a slightly higher efficiency in the league.

They got a bit more clinical in the second half and took QPR to the woodshed with four goals.

It was a great win for us, however we need to be more clinical in front of goal.

Which means «ALL» of our forward players need to be more clinical in front of goal.

We can be ruthless on the counter too but we really need to be more clinical in front of goal, no matter the style we impose on the day, even if its smash and grab, we need to put our chances away and kill teams off early

You'll find all our guys need to be more clinical in front of goal.

Afobe being stronger, quicker, and more clinical in front of goal than any of our current front men save Alexis and maybe Theo... Go figure.

We do need a different type of striker, with pace and dribbling skill, who can get in behind opponent defence, and more clinical in front of goal.

hope to God that Theo will become more clinical in front; versus wolfsburg he let 2 get away [but got 1]

Now the season is over and he is over in Dubai at an Arsenal Soccer School, and he is obviously hoping to beat that record very easily next season, but he can't do that unless Arsenal invest in some «strong players» that can be a bit more clinical in front of goal.

he just needs to work on his striking more, I think he can be so much more clinical in the front (be that in mind he has put in some very nicely placed goals) And do you know what i agree with you in terms of a striker I want Alvaro Morata..

In this leg we will have to be more clinical in order to go through

We've even been a bit more clinical in front of goal, and a little less careless at the back, or more careful.

If we were more clinical in front of the goal our midfield wouldn't be feeling all the pressure.

Not exact matches

The Chinese government financed nationwide studies into cockroaches» medical value that, after more than two decades of laboratory investigation and clinical trials, had discovered or confirmed dozens of disease - fighting proteins and biochemical compounds with huge potential value in medicine.

There are more than 80 immune - related cancer therapies currently in clinical trials, fueled by many billions of dollars in pharmaceutical investment from the likes of Bristol - Myers Squibb bmy, Merck mrk, Pfizer pfe, and dozens of biotechs.

In an editorial about Theranos in the journal Clinical Chemistry and Laboratory Medicine earlier this year, Eleftherios P. Diamandis, the head of clinical biochemistry at Mount Sinai Hospital in Toronto, argued that fingerprick tests are not necessarily any more painful than needle draws — though there still might be an appeal for someone afraid of needleIn an editorial about Theranos in the journal Clinical Chemistry and Laboratory Medicine earlier this year, Eleftherios P. Diamandis, the head of clinical biochemistry at Mount Sinai Hospital in Toronto, argued that fingerprick tests are not necessarily any more painful than needle draws — though there still might be an appeal for someone afraid of needlein the journal Clinical Chemistry and Laboratory Medicine earlier this year, Eleftherios P. Diamandis, the head of clinical biochemistry at Mount Sinai Hospital in Toronto, argued that fingerprick tests are not necessarily any more painful than needle draws — though there still might be an appeal for someone afraid of Clinical Chemistry and Laboratory Medicine earlier this year, Eleftherios P. Diamandis, the head of clinical biochemistry at Mount Sinai Hospital in Toronto, argued that fingerprick tests are not necessarily any more painful than needle draws — though there still might be an appeal for someone afraid of clinical biochemistry at Mount Sinai Hospital in Toronto, argued that fingerprick tests are not necessarily any more painful than needle draws — though there still might be an appeal for someone afraid of needlein Toronto, argued that fingerprick tests are not necessarily any more painful than needle draws — though there still might be an appeal for someone afraid of needles.

«Over time, we've been optimizing our clinical lab to bring up tests that are more commonly ordered, and in some cases move resources off the proprietary tests that are less commonly ordered to get to a point where the ordering patterns we are seeing can all be accommodated through our finger - stick technology.»

The company has raised just under $ 1 million and plans to raise several million more in a Series A to fund clinical trials.

Among them: «a lack of data standards in treating cancer, lack of data sharing in the research and development enterprise, lack of patient input and participation in clinical trials,» and more.

That provision would have allowed approved drugs that win additional FDA clearances to treat rare disorders — i.e., those that affect 200,000 or fewer Americans — extended market exclusivity in the hopes that biopharma companies would be more compelled to invest in difficult - to - treat spaces that involve costly follow - on clinical trials.

The researchers found that Theranos was likely to be more accurate in testing for white blood cells, but wrote that «additional precision was unlikely to alter clinical decisions.»

«Through this collaboration with the cancer community's leading clinical and pathology experts, thousands of more patients can potentially benefit from the world's growing body of knowledge about this disease,» said IBM Research and Cognitive Solutions senior vice president John Kelly in a statement.

Taking this drug daily has shown to offer more than 90 % (and as much as 99 %) effective protection against HIV in clinical trials, and certain New Zealand residents will soon be able to get a three - month supply for just $ 5 (oh, and that's five New Zealand dollars, which is about $ 3.64 in U.S. money).

Our range of clinical capabilities, resources and tools — such as in - home care, behavioral health, pharmacy services, data analytics and wellness solutions — combine to produce a simplified experience that makes health care easier to navigate and more effective.

According to PhRMA, there are more than a dozen experimental treatments that are still in phase 3, the latest stage of clinical trials before companies present their data to the FDA.

One example could be more active involvement in funding research and awareness about the disease; another might include offering paid leave or compensation for employees who participate in Alzheimer's clinical trials.

Ashish Jha, the senior author of the JAMA Internal Medicine paper, points out in a blog post that there are reasons why women doctors might well deliver better care, citing research to suggest that they might adhere more closely to established clinical practice guidelines and that patients often report better personal experiences (something that ultimately might lead to better outcomes).

There are several drugs to treat ALS currently in clinical trials and we are hopeful that people living with ALS have even more therapies available to them sooner rather than later.»

That could be key as more cutting - edge therapies try to find success in clinical trials.

Now that the barrier of editing genes in the hospital setting has been broken, these companies and more have pipelines of gene - editing innovation coming to a hospital near you in the next few years, as clinical trials are approved and new ways to cure formerly incurable diseases go mainstream in our lifetimes.

In a clinical trial of more than 600 participants, Empliciti, when used with cancer drug Revlimid and steroid dexamethasone was better at delaying when the cancer worsened than just the two drugs alone.

The Director of Clinical Operations for the Penn State Heart & Vascular Institute, Ettinger is described as «one of the best students I have seen in more than 30 years of teaching Executive MBA students» by Dennis P. Sheehan, the school's faculty director for MBA programs.

«[W] e found that when it came to obstacles outside of clinical treatment we were in search of more support,» he says.

While Yervoy brought in $ 960 million in sales in 2013 (an enormous figure for a two - year - old drug with a small patient population), the company currently has more than 35 ongoing clinical trials investigating another drug that disengages the immune system's brakes: the much - awaited nivolumab, which was also from the Medarex portfolio.

MEDIAL EARLYSIGN SHOWS AI AND EHR DATA CAN BE USED FOR EARLY DETECTION: Researchers from Medial EarlySign, a provider of machine - learning solutions, found that the combination of machine learning technology and electronic health record (EHR) data can be more effective than current clinical tools in identifying the risk of kidney damage in diabetics.

The case was yet more evidence that both the clinical trial doctors and the drug's developers would have to be more patient in assessing this new type of therapy.

Novartis has several more biosimilars marketed in other countries (as well as an FDA approved copycat of Amgen's bestselling treatment Enbrel, which hasn't reached the U.S. yet due to patent spats), and three others in late - stage clinical development.

In fact, one of Marathon's clinical trials that the FDA used as part of its decision - making process was conducted more than 20 years ago, saving the firm plenty of study costs.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).